Revascularization therapy similar for drug-coated balloon versus uncoated balloon, drug-eluting stent
THURSDAY, April 28, 2016 (HealthDay News) — For infrapopliteal arteries, revascularization therapy with drug-coated balloon (DCB) is associated with similar clinical outcomes as uncoated balloon or drug-eluting stent, according to a review and meta-analysis published online April 27 in JACC: Cardiovascular Interventions.
Salvatore Cassese, M.D., Ph.D., from the Deutsches Herzzentrum München in Germany, and colleagues performed a meta-analysis of randomized trials to examine the role of DCB as revascularization therapy for infrapopliteal arteries. Data were included for 641 patients enrolled in five trials who received DCB (378 patients) or control therapy (uncoated balloon/drug-eluting stent, 263 patients). Patients were followed for a median of 12 months.
The researchers found that, compared with control-treated patients, patients treated with DCB had comparable risks of target lesion revascularization (risk ratio [RR], 0.71; 95 percent confidence interval [CI], 0.47 to 1.09), amputation (RR, 1.01; 95 percent CI, 0.65 to 1.58), death (RR, 1.14; 95 percent CI, 0.71 to 1.82), major adverse events (RR, 0.92; 95 percent CI, 0.59 to 1.43), and Rutherford class 5 to 6 (RR, 0.87; 95 percent CI, 0.46 to 1.62). Late lumen loss was lower for lesions treated with DCB versus control therapy (weighted mean difference, −0.41; P = 0.04).
“Further studies in larger number of patients are still needed to definitively address the role of DCB technology in this setting,” the authors write.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
